NEU 3.50% $14.05 neuren pharmaceuticals limited

TROFINETIDE TRIALS UPDATE, page-77

  1. 109 Posts.
    lightbulb Created with Sketch. 38
    With many participants now months into Lilac, the dropout rate is likely compelling evidence for the success/failure of P3. However I doubt that this information will be obtainable from Acadia or Neuren.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.